Phase 2 Pancreatic Cancer Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who have been diagnosed with a confirmed type of pancreatic cancer called pancreatic ductal adenocarcinoma, specifically classified as "locally advanced" (meaning it has grown but has not spread to other parts of the body)
• People whose cancer shows no signs of having spread to the lining of the abdomen or through the bloodstream to other organs
• People whose cancer has been assessed by a team including at least an oncologist, a radiologist, and a qualified surgeon, and has been classified as unable to be removed by surgery, based on scans
• People whose tumor can be measured using standard imaging guidelines (called RECIST criteria v1.1)
• People who have at least one tumor area that is 3.5 cm or smaller and is suitable for a needle injection and biopsy guided by ultrasound
• People whose general health and ability to carry out daily activities falls within an acceptable range (rated 0, 1, or 2 on a standard scale called the ECOG performance status)
• People whose health condition means a treating doctor would consider them suitable for standard chemotherapy treatment
• People aged 18 years or older
• People with adequate liver, kidney, and blood function as assessed through testing
• Women who could become pregnant must have a negative blood pregnancy test within the required timeframe before starting treatment
• People who are willing and able to attend scheduled visits, follow the treatment plan, and take part in all study procedures, including a fat tissue collection procedure (liposuction)

Who may not be able to join:

• People with a cystic (fluid-filled) pancreatic tumour or a pancreatic pseudocyst
• People with a type of pancreatic tumour other than adenocarcinoma, such as an endocrine tumour or a tumour that has spread from another cancer
• People whose pancreatic cancer stage is unknown or whose cancer has returned after previous treatment
• People with a weakened immune system or known susceptibility to viral infections
• People with active infections including HIV, hepatitis B, hepatitis C, HTLV-I/II, or syphilis (Treponema pallidum)
• People with liver cirrhosis or other confirmed liver disease
• People for whom chemotherapy would be medically unsuitable
• People who have previously received radiotherapy or chemotherapy for pancreatic ductal adenocarcinoma
• People who have previously had a stem cell transplant or an organ transplant
• People with permanent, uncontrollable heart rhythm problems that require ongoing medication
• People with heart failure rated above Grade II on the New York Heart Association scale
• People who have had a heart attack, unstable angina, or severe stable angina within the past year
• People with high blood pressure that is not well controlled
• People who have had another cancer within the past two years (with some exceptions, such as certain skin, prostate, or cervical cancers — confirm with trial site)
• People with an active autoimmune disease
• People who have taken part in another clinical trial and received an experimental treatment within the 21 days before the study treatment begins
• People who have had major open surgery shortly before the study treatment is due to start (confirm exact timeframe with trial site)
• People with uncontrolled ongoing illness, including certain mental health or social circumstances that, in the investigator's view, could affect safe participation
• People with a known or suspected allergy or sensitivity to a class of antibiotics called fluoroquinolones, including ciprofloxacin
• People with a known or suspected allergy or sensitivity to protamine sulfate or products containing protamine — this may include people who have had certain heart procedures, people with diabetes who have used protamine insulin, people with a fish allergy, or men who have had a vasectomy or are infertile and may have developed antibodies to protamine

Important: Always verify eligibility with the trial site directly before applying.